SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 3, 2017, James Topper notified Sierra Oncology, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) and the Nominating and Corporate Governance Committee (the “Nominating Committee”), effective April 10, 2017. In connection with Dr. Topper’s resignation, the Board appointed Donald Parfet as the interim Chair of the Nominating Committee, effective April 10, 2017. Dr. Topper’s decision was not the result of any disagreement with the Company.

On April 3, 2017, the Board appointed Daniel Estes to the Board as a Class II director, effective April 10, 2017. There is no arrangement or understanding with any person to which Dr. Estes was appointed as a member of the Board. There are also no family relationships between Dr. Estes and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.

Dr. Estes will receive compensation in accordance with the Company’s existing non-employee director compensation program adopted by the Board from time to time. The Company’s non-employee director compensation program is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2016.

The Company also intends to enter into its standard form of indemnification agreement with Dr. Estes. A form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 15, 2015.

2

About SIERRA ONCOLOGY, INC. (NASDAQ:SRRA)

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Recent Trading Information

SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) closed its last trading session down -0.04 at 1.43 with 319,321 shares trading hands.